SRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
Benzinga Newsdesk 2 months ago
M&AHealth CareGeneralBiotech
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.